Welcome to our dedicated page for PetMed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on PetMed Express stock.
PetMed Express, Inc. (NASDAQ: PETS), widely recognized as PetMeds, is America's largest pet pharmacy. Established in 1996, PetMeds provides both prescription and non-prescription pet medications, health products, and nutritional supplements for dogs, cats, and horses directly to consumers at substantial savings. The company operates from a single location, delivering exceptional value and convenience to millions of satisfied customers nationwide.
PetMeds generates revenue primarily by selling pet medications and supplies, targeting retail consumers. The company prides itself on being a trusted pet health expert, offering competitive prices and convenient access to a wide range of products. Pet parents can purchase these products through PetMeds' toll-free number (1-800-PetMeds) or online at www.petmeds.com.
Recently, PetMeds partnered with Hill's Pet Nutrition to offer Hill's Science Diet products on PetMeds' platform starting March 1, 2024. To celebrate this partnership, PetMeds launched a promotional giveaway, providing a year's worth of Hill's Science Diet to one lucky winner. This initiative aligns with PetMeds' commitment to responsible pet ownership and support for animal shelters facing capacity crises.
PetMeds also offers innovative services like Pumpkin® pet insurance plans and same-day VetLive® telehealth appointments, making veterinary care more accessible and affordable. Furthermore, through its wholly-owned subsidiary, PetCareRx, PetMeds extends its reach by providing additional pet health products and services.
The company's financial stability is underscored by its consistent performance and strategic partnerships. PetMeds is scheduled to host a conference call on February 8, 2024, to discuss its third-quarter results, followed by a Q&A session. This event provides an opportunity for investors and stakeholders to gain insights into the company's operations and future plans.
For more information, visit www.petmeds.com or contact PetMeds' investor relations team at investor@petmeds.com.
PetMed Express, Inc. (NASDAQ: PETS) has completed the acquisition of PetCareRx for approximately $36 million in cash. This strategic move expands PetMeds' market reach from pet medications to a wider healthcare category. With the addition of around 10,000 new food, diet, and wellness products, PetMeds aims to enhance its product offerings and service capabilities for its over two million active customers. The acquisition will allow PetMeds to leverage a more efficient distribution network while maintaining the independent operation of PetCareRx's e-commerce platform, ensuring continuity in customer experience.
PetMed Express, Inc. (NASDAQ: PETS) reported its financial results for Q3 FY 2023, with net sales of $58.9 million, marking a 3% decline year-over-year. The company recorded a net loss of $19,000, translating to $(0.00) per diluted share, down from a net income of $4.3 million or $0.21 per share in the same quarter last year. Adjusted EBITDA fell 64% to $2.7 million. However, new customers increased by 9% year-over-year, the first rise in 10 quarters. The Board declared a $0.30 quarterly dividend, payable on February 27, 2023. Management believes ongoing investments, including the acquisition of PetCareRx, will foster long-term growth.
PetMed Express (PETS) has announced a conference call scheduled for February 6, 2023, at 4:30 PM Eastern Time to discuss its third-quarter financial results for the period ending December 31, 2022. This call will be preceded by a press release detailing the financial results. Interested parties can join via a U.S. dial-in number or international line, and a replay will be available until February 20, 2023. PetMed Express, founded in 1996, provides prescription and non-prescription medications for pets through its 1-800-PetMeds service and website. Key risks and uncertainties, including the company's ability to fulfill its business objectives, are noted in their SEC filings.
PetMed Express has announced the acquisition of PetCareRx, a key player in pet medications and supplies. This strategic move aims to enhance revenue and expand its market share in the $120 billion U.S. pet care sector. PetMed plans to integrate an additional 10,000 wellness products, boosting their customer base of over two million. The acquisition is expected to close in Q1 2023, pending regulatory approval. CEO Matt Hulett emphasizes that the merger will offer customers increased choices and drive long-term shareholder value. The PetCareRx brand will continue separately, ensuring a seamless service experience.
PetMed Express announced its financial results for the second quarter ended September 30, 2022, reporting net sales of $65.4 million, down 3.0% from $67.4 million in the same period last year. Net income decreased to $2.6 million or $0.13 EPS, compared to $6.3 million or $0.31 EPS a year prior. Adjusted EBITDA also fell by 28% to $7.1 million. Despite these declines, the company noted growth in AutoShip & Save subscriptions, now making up 39% of total sales. A quarterly dividend of $0.30 per share was declared, payable on November 30, 2022.
FAQ
What is the current stock price of PetMed Express (PETS)?
What is the market cap of PetMed Express (PETS)?
What does PetMed Express, Inc. do?
Where can I buy PetMeds products?
What recent partnerships has PetMeds announced?
What is the significance of PetMeds’ partnership with Hill's Pet Nutrition?
Does PetMeds offer pet insurance?
What other services does PetMeds provide?
Who are PetMeds' primary customers?
When is PetMeds' next conference call?
How can I contact PetMeds for investor relations?
What is PetCareRx?
